- Home
- HSAI vs NAMS Comparison
HSAI vs NAMS Comparison
Compare HSAI & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HSAI | NAMS |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | China | Netherlands |
| Employees | 1024 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.5B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | HSAI | NAMS |
|---|---|---|
| Price | $26.89 | $35.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $31.58 | ★ $47.33 |
| AVG Volume (30 Days) | ★ 1.8M | 631.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $55.45 | $38.17 |
| Revenue Next Year | $39.33 | $573.62 |
| P/E Ratio | $61.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.41 | $14.06 |
| 52 Week High | $30.85 | $42.00 |
Technical Indicators
Market Signals| Indicator | HSAI | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 53.54 | 53.77 |
| Support Level | $22.10 | $34.05 |
| Resistance Level | $28.56 | $37.43 |
| Average True Range (ATR) | 1.52 | 1.76 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 53.36 | 44.37 |
Price Performance
Historical ComparisonAbout HSAI Hesai Group each ADS represents one Class B ordinary share
Hesai Group is engaged in the development, manufacture, and sales of three-dimensional light detection and ranging solutions, or LiDAR. Its LiDAR products enable a broad spectrum of applications across passenger or commercial vehicles with enhanced advanced driver assistance systems, or ADAS, autonomous vehicle fleets providing passenger and freight mobility services, or Autonomous Mobility, and other applications such as last-mile delivery robots, street sweeping robots, and logistics robots in restricted areas, or Robotics. Geographically, the company operates in North America, Mainland China, Europe, and Other regions.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.